A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas

Neuro-Oncology

Volumn 12, Issue 1, 2010, Pages 87-94

  Raizer, Jeffrey J ^a   Abrey, Lauren E ^b   Lassman, Andrew B ^b   Chang, Susan M ^c   Lamborn, Kathleen R ^c   Kuhn, John G ^d   Yung, W K Alfred ^e   Gilbert, Mark R ^e   Aldape, Kenneth D ^e   Wen, Patrick Y ^f   Fine, Howard A ^g   Mehta, Minesh ^h   DeAngelis, Lisa M ^b   Lieberman, Frank ⁱ   Cloughesy, Timothy F ^j   Robins, H Ian ^h   Dancey, Janet ^k   Prados, Michael D ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h University of Wisconsin Health   (United States)

ⁱ UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

more..

Author keywords

Erlotinib; Glioblastoma; Glioma; Meningioma; Pharmacokinetics

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CP 396059; ERLOTINIB; OSI 420; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRY SKIN; FATIGUE; FEMALE; GLIOBLASTOMA; GRANULOCYTOPENIA; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOCYTE COUNT; LEUKOPENIA; LUNG EMBOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MENINGIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OLIGODENDROGLIOMA; PHASE 1 CLINICAL TRIAL; PRURITUS; RECURRENT CANCER; RIGOR; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; YOUNG ADULT;

EID: 75749110539     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop017     Document Type: Article

References (16)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
2. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996;56:5079-5086.
3. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA. 1994;91:7727-7731.
4. Han Y, Caday CG, Umezawa K, et al. Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate. Oncol Res. 1997;9:581-587.
5. Mishima K, Johns TG, Luwor RB, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001;61:5349-5354.
6. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024.
7. Nathoo N, Goldlust S, Vogelbaum MA. Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery. 2004;54:1480-1488.
8. Ling J, Fettner S, Lum BL, et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs. 2008;19:209-216.
9. Rakhit A, Pantze MP, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYPtrade mark) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol. 2008;64:31-41.
10. Fetell MR, Grossman SA, Fisher JD, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol. 1997;15:3121-3128.
11. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12:4899-4907.
12. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res. 2005;11:7841-7850.
13. Macdonald DR, Cascino TL, Schold SC, Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
14. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-Oncology. 2006;8: 67-78.
15. Rasheed BK, Wiltshire RN, Bigner SH, et al. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol. 1999;11:162-167.
16. Sehgal A: Molecular changes during the genesis of human gliomas. Semin Surg Oncol. 1998;14:3-12.